- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01851538
The Role of Biomarkers and Echocardiography in Prediction of Prognosis of Chronic Heart Failure Patients (Bio-SHiFT)
Serial Biomarker Measurements and New Echocardiographic Techniques in Chronic Heart Failure Patients Result in Tailored Prediction of Prognosis
The Bio-SHiFT study aims to investigate whether disease progression in individual patients with chronic heart failure (CHF) can be accurately assessed by serial measurements of disease-related (novel) biomarkers. Secondary objectives of the study include comparison of 2D- with real-time 3D-echocardiography in CHF patients and comparison of Speckle tracking with tissue Doppler imaging (TDI) in CHF patients, and relating these echocardiographic measurements to clinical outcome.
Bio-SHiFT is a prospective, observational, multi-center, cohort study in men and women, aged 18 years or older, visiting the outpatient clinic. Blood samples are taken at the day of inclusion and at follow-up visits, which are performed every 3 months until the end of the scheduled follow-up. Clinical data are collected at baseline and at each 3-month follow-up visit. Echocardiography including TDI, Speckle tracking and 3D-echocardiography is performed in a subset of patients, at baseline and during follow-up at 6-month intervals. The primary endpoint is the composite of cardiovascular death, cardiac transplantation, left ventricular assist device implantation, and re-hospitalization for the management of acute or worsened heart failure.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Alkmaar, Nederländerna
- Medical Center Alkmaar
-
Rotterdam, Nederländerna
- Erasmus MC
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Men and women, aged 18 years or older, capable of understanding and signing informed consent
- Diagnosis of chronic heart failure (with diminished ejection fraction or with normal ejection fraction), according to the guidelines of the European Society of Cardiology (ESC)
Exclusion Criteria:
- Heart failure secondary to circulatory high output conditions
- Scheduled for surgery or intervention for both coronary and non-coronary indication
- Severe renal failure for which dialysis is needed
- Known moderate or severe liver disease
- Chronic Obstructive Pulmonary Disease (COPD) Gold stage IV
- Congenital heart disease
- Coexistent condition with life expectancy ≤ 1 year
- Unlikely to appear at all scheduled follow-up visits
- Linguistic barrier
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Chronic heart failure patients visiting the outpatient clinic
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
The composite of cardiovascular death, cardiac transplantation, left ventricular assist device implantation, and re-hospitalization for the management of acute or worsened heart failure.
Tidsram: maximum follow-up is 2.5 years
|
maximum follow-up is 2.5 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Cardiovascular death
Tidsram: maximum follow-up is 2.5 years
|
maximum follow-up is 2.5 years
|
|
Cardiac transplantation
Tidsram: maximum follow-up is 2.5 years
|
maximum follow-up is 2.5 years
|
|
Left ventricular assist device implantation
Tidsram: maximum follow-up is 2.5 years
|
maximum follow-up is 2.5 years
|
|
Re-hospitalization for acute or worsened heart failure
Tidsram: maximum follow-up is 2.5 years
|
maximum follow-up is 2.5 years
|
|
Cardiovascular disease: myocardial infarction (fatal and non-fatal), stroke (fatal and non-fatal), percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG)
Tidsram: maximum follow-up is 2.5 years
|
Cardiovascular disease, comprising all events specified above, will be examined, as well as all individual components.
|
maximum follow-up is 2.5 years
|
All-cause mortality
Tidsram: maximum follow-up is 2.5 years
|
maximum follow-up is 2.5 years
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studiestol: Eric Boersma, MSc, PhD, Erasmus Medical Center
- Studierektor: Isabella Kardys, MD, PhD, Erasmus Medical Center
- Huvudutredare: Victor Umans, MD, PhD, Medical Center Alkmaar
- Huvudutredare: Martijn Akkerhuis, MD, PhD, Erasmus Medical Center
Publikationer och användbara länkar
Allmänna publikationer
- Klimczak-Tomaniak D, de Bakker M, Bouwens E, Akkerhuis KM, Baart S, Rizopoulos D, Mouthaan H, van Ramshorst J, Germans T, Constantinescu A, Manintveld O, Umans V, Boersma E, Kardys I. Dynamic personalized risk prediction in chronic heart failure patients: a longitudinal, clinical investigation of 92 biomarkers (Bio-SHiFT study). Sci Rep. 2022 Feb 18;12(1):2795. doi: 10.1038/s41598-022-06698-3.
- Bouwens E, Schuurman AS, Akkerhuis KM, Manintveld OC, Caliskan K, van Ramshorst J, Germans T, Umans VA, Boersma E, Kardys I. Associations of serially measured PCSK9, LDLR and MPO with clinical outcomes in heart failure. Biomark Med. 2021 Mar;15(4):247-255. doi: 10.2217/bmm-2020-0585. Epub 2021 Feb 16.
- Bouwens E, Brankovic M, Mouthaan H, Baart S, Rizopoulos D, van Boven N, Caliskan K, Manintveld O, Germans T, van Ramshorst J, Umans V, Akkerhuis KM, Kardys I. Temporal Patterns of 14 Blood Biomarker candidates of Cardiac Remodeling in Relation to Prognosis of Patients With Chronic Heart Failure-The Bio- SH i FT Study. J Am Heart Assoc. 2019 Feb 19;8(4):e009555. doi: 10.1161/JAHA.118.009555.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- MEC-2011-029
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hjärtsvikt
-
Region SkaneAnmälan via inbjudanHjärtsvikt New York Heart Association (NYHA) klass II | Hjärtsvikt New York Heart Association (NYHA) klass IIISverige
-
Taichung Veterans General HospitalRekryteringKontinuerlig Fetal Heart Beat Monitor och analys efter Spinal AnestesiTaiwan
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan... och andra samarbetspartnersHar inte rekryterat ännuHjärtsvikt, systolisk | Hjärtsvikt Med Minskad Ejection Fraktion | Hjärtsvikt New York Heart Association Klass IV | Hjärtsvikt New York Heart Association Klass IIIPolen
-
University of WashingtonAmerican Heart AssociationAvslutadHjärtsvikt, Kongestiv | Mitokondriell förändring | Hjärtsvikt New York Heart Association Klass IVFörenta staterna
-
Novartis PharmaceuticalsAvslutadPatienter som framgångsrikt slutfört den 12 månader långa behandlingsperioden i kärnstudien (de Novo Heart Recipients) som var intresserade av att bli behandlad med EC-MPS
-
University Hospital, GasthuisbergOkändTransient Left Ventricular Ballooning SyndromeBelgien
-
Children's Hospital Medical Center, CincinnatiRekryteringNationellt samarbete för att förbättra vården av barn med komplexa medfödda hjärtsjukdomar (NPC-QIC)Hypoplastiskt Left Heart Syndrome (HLHS)Förenta staterna, Storbritannien, Kanada
-
Lifetech Scientific (Shenzhen) Co., Ltd.OkändPatent Ductus Arteriosus | Kanalberoende Cyanotic Congenital Heart DiseaseMalaysia
-
Mayo ClinicRekryteringHypoplastiskt Left Heart Syndrome (HLHS)Förenta staterna
-
NYU Langone HealthRekryteringTako-tsubo kardiomyopati | Takotsubo kardiomyopati | Broken Heart SyndromeFörenta staterna
Kliniska prövningar på Observational study; no intervention.
-
Clinical Research Centre, MalaysiaHospital Queen Elizabeth, MalaysiaAvslutadCovid19 | Kritiskt sjukMalaysia
-
Columbia UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... och andra samarbetspartnersAvslutad
-
Escola Superior de Tecnologia da Saúde do PortoAvslutad
-
Seoul National University HospitalDong-A ST Co., Ltd.Har inte rekryterat ännuCovid-19Korea, Republiken av